# US 2017/0254814 A1 · Rapid Screening And Evaluation Of Diabetes And Prediabetes By Glycated Hemoglobin Mass Spectrometry

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0254814 A1
- Document ID: US20170254814A1
- Status: Published application
- Kind: A1
- Application number: 15/506,731
- Filed: 2015-08-27
- Published: 2017-09-07
- Earliest claimed: 2014-08-29
- Assignees: Map IP Holding Limited
- Applicants: Map IP Holding Limited
- Inventors: Raymond Kruse Iles
- Web page: https://patentgrep.com/patent/US20170254814A1

## CPC

- G01N 33/6851: {Methods of protein analysis involving laser desorption ionisation mass spectrometry}
- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- G01N 33/723: {Glycosylated haemoglobin}
- G01N 2800/042: Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The method describes rapid screening of whole blood samples, pin prick and blood spot cards, subjected to MALDI-ToF Mass spectrometry. The spectra is generated and compared to those from normal healthy controls. Characteristic spectra are indicative of the presence of a hemoglobinopathy and the method can be used to screen/diagnose all sickle cell diseases, alpha and beta Thalassemias.

## Claims

### Claim 1

A method of detecting prediabetes or diabetes comprising subjecting a blood sample obtained from a subject to direct mass spectral analysis and determining the proportion of glycated hemoglobin (Hb) present in the sample.

### Claim 2 (depends on 1)

The method according to claim 1 wherein determining the proportion of glycated hemoglobin present comprises measuring (i) the levels of glycated α globin and unglycated α globin and/or (ii) the levels of glycated β globin and unglycated β globin.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the blood sample is lysed prior to said direct mass spectral analysis.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the blood sample is diluted prior to direct mass spectral analysis.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the sample subjected to direct mass spectral analysis is not processed other than lysis and/or dilution.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the spectra obtained from the direct mass spectral analysis is normalized.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the proportion of glycated hemoglobin is calculated as the percentage glycated hemoglobin.

### Claim 8 (depends on 1)

The method according to claim 1 wherein the spectra obtained from the direct mass spectral analysis is examined in the range 7,000 to 16,500 m/z.

### Claim 9 (depends on 1)

The method according to claim 1, wherein determining the proportion of glycated hemoglobin comprises measuring the levels of the singly charged hemoglobin or globin molecules.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the spectra obtained from the direct mass spectral analysis is examined in the range 15,000 to 16,200 m/z.

### Claim 11 (depends on 1)

The method according to claim 1, wherein determining the proportion of glycated hemoglobin comprises measuring the levels of the doubly charged hemoglobin or globin molecules.

### Claim 12 (depends on 11)

The A method according to claim 11, wherein the spectra obtained from the direct mass spectral analysis is examined in the range 6,000 to 8,100 m/z.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the amount of glycated Hb and unglycated Hb is measured using the total area under the curve of the mass spectra obtained from the direct mass spectral analysis.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the amount of glycated Hb and unglycated Hb is measured using the relative peak height of the mass spectra obtained from the direct mass spectral analysis.

### Claim 15 (depends on 1)

The method according to claim 1, wherein a percentage of glycated α-globin between 3-4% and/or a percentage of glycated β-globin between 3-6% is indicative of pre-diabetes.

### Claim 16 (depends on 1)

The method according to claim 1, wherein a percentage glycated α globin >4% and/or a percentage glycated β-globin >6% is indicative of diabetes.

### Claim 17 (depends on 1)

The method according to claim 1, wherein the mass spectral analysis carried out is matrix-assisted laser desorption/ionization spectrometry (MALDI).

### Claim 18 (depends on 17)

The method according to claim 17, wherein the MALDI spectrometry is time-of-flight mass spectrometry (MALD-ToF MS).
